Clinical Studies

  1. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis; George Krasopoulos, cardiovascular surgery fellow, Stephanie J Brister, associate professor, W Scott Beattie, R Fraser Elliot chair in cardiac anaesthesia, Michael R Buchanan, professor ; doi:10.1136/bmj.39430.529549.BE
  2. The Role of Homocysteine-Lowering B-Vitamins in the Primary Prevention of Cardiovascular Disease; Balazs Debreceni1 & Laszlo Debreceni2 Cardiovascular Therapeutics 32 (2014) 130–138
  3. Folic acid supplementation of aspirin therapy further improves vascular endothelial function among patients with type 2 diabetes: a short-term crossover study; Shuichi Sato, Yuji Tajiri, Hitomi Nakayama , Kentaro Yamada; DOI 10.1007/s13340-014-0198-3
  4. Plasma Homocysteine as a Risk Factor for Vascular Disease- The European Concerted Action Project JAMA, June 11, 1997—Voi 277, No. 22 Homocysteine and Vascular Disease Risk—Graham et al
  5. Combined effect of GSTM1 gene deletion, GSTT1 gene deletion and MTHFR C677T mutation in male infertility V. Đorđević et al. Arch. Biol. Sci., Belgrade, 62 (3), 531-530, 2010
  6. Folate and Vitamin B6 From Diet and Supplements in Relation to Risk ofCoronary Heart Disease Among Women; Eric B. Rimm; Walter C. Willett; Frank B. Hu; et al.JAMA, February 4, 1998—Vol 279, No. 5
  7. Prevalence of Factor V Leiden, Factor V Cambridge, Factor II G20210A and Methylenetetrahydrofolate Reductase C677TMutations in Healthy and ThrombophilicSerbian Populations Djordjevic/Rakicevic/Mikovic/Kovac/ Miljic/Radojkovic/Savic May 6, 2004
  8. Pharmacokinetic study on the utilisation of 5- methyltetrahydrofolate and folic acid in patients with coronary artery disease; F.F. Willems et al; British Journal of Pharmacology (2004) 141, 825–830
  9. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis.Wang X1, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X.; Lancet. 2007 Jun 2;369(9576):1876-82
  10. Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease-A Meta-Analysis of Prospective Studies-Lu Wang, MD, PhD*, Yiqing Song, MD, ScD*, JoAnn E. Manson, MD, DrPH, Stefan Pilz, MD, Winfried März, MD, Karl Michaëlsson, MD, PhD, Annamari Lundqvist, PhD, Simerjot K. Jassal
  11. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990;19:559–563.
  12. Poole KE, Loveridge N, Barker PJ, Halsall DJ, Rose C, Reeve J, Warburton EA. Reduced vitamin D in acute stroke. Stroke. 2006;37:243–245.
  13. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:1179–1185.
  14. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland.K. Nyyssönen, M. T. Parviainen, R. Salonen, J. Tuomilehto, and J. T. Salonen BMJ. Mar 1, 1997; 314(7081): 634–638
  15. Homocysteine is a novel risk factor for suboptimal response of blood platelets toacetylsalicylic acid in coronary artery disease: A randomized multicenter study; Kamil Karolczaka, Wojciech Kamyszb, Anna Karafovab, Jozef Drzewoskic, Cezary Watala; Pharmacological Research 74 (2013) 7– 22
  16. Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults With Hypertension in China, The CSPPT Randomized Clinical Trial; Yong Huo, MD; Jianping Li, MD, PhD; Xianhui Qin, PhD; Yining Huang, MD et al; JAMA, March 15, 2015. – doi:10.1001/jama.2015.2274
  17. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Koyama K1, Usami T, Takeuchi O, Morozumi K, Kimura G. Nephrol Dial Transplant. 2002 May;17(5):916-22.